Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Autor: Li R; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.; Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org., Shah PH; Department of Urology, Mayo Clinic, Rochester, MN, USA., Stewart TF; Department of Medicine, UC San Diego, La Jolla, CA, USA., Nam JK; Pusan National University, Yangsan Hospital, Yangsan, South Korea., Bivalacqua TJ; Department of Urology, University of Pennsylvania, Philadelphia, PA, USA., Lamm DL; BCG Oncology, Phoenix, AZ, USA., Uchio EM; Department of Urology, UC Irvine, Irvine, CA, USA., Geynisman DM; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Jacob JM; Department of Urology, SUNY Medical Center, Upstate, Syracuse, NY, USA., Meeks JJ; Department of Urology, Northwestern University Medical Center, Chicago, IL, USA., Dickstein R; Chesapeake Urology, Hanover, MD, USA., Pearce SM; Spokane Urology, Spokane, WA, USA., Kang SH; Korea University, Anam Hospital, Seoul, South Korea., Jung SI; Chonnam National University, Hwasun Hospital, Bundang, South Korea., Kamat AM; Department of Urology, UT MD Anderson Cancer Center, Houston, TX, USA., Burke JM; Billings Clinic, Billings, MT, USA., Keegan KA; CG Oncology, Irvine, CA, USA.; Department of Urology, Vanderbilt University, Nashville, TN, USA., Steinberg GD; Department of Urology, Rush University Medical Center, Chicago, IL, USA.

Publikováno v: Nature medicine [Nat Med] 2024 Aug; Vol. 30 (8), pp. 2372.

Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.

Autor: Li R; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.; Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org., Shah PH; Department of Urology, Mayo Clinic, Rochester, MN, USA., Stewart TF; Department of Medicine, UC San Diego, La Jolla, CA, USA., Nam JK; Pusan National University, Yangsan Hospital, Yangsan, South Korea., Bivalacqua TJ; Department of Urology, University of Pennsylvania, Philadelphia, PA, USA., Lamm DL; BCG Oncology, Phoenix, AZ, USA., Uchio EM; Department of Urology, UC Irvine, Irvine, CA, USA., Geynisman DM; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Jacob JM; Department of Urology, SUNY Medical Center, Upstate, Syracuse, NY, USA., Meeks JJ; Department of Urology, Northwestern University Medical Center, Chicago, IL, USA., Dickstein R; Chesapeake Urology, Hanover, MD, USA., Pearce SM; Spokane Urology, Spokane, WA, USA., Kang SH; Korea University, Anam Hospital, Seoul, South Korea., Jung SI; Chonnam National University, Hwasun Hospital, Bundang, South Korea., Kamat AM; Department of Urology, UT MD Anderson Cancer Center, Houston, TX, USA., Burke JM; Billings Clinic, Billings, MT, USA., Keegan KA; CG Oncology, Irvine, CA, USA.; Department of Urology, Vanderbilt University, Nashville, TN, USA., Steinberg GD; Department of Urology, Rush University Medical Center, Chicago, IL, USA.

Publikováno v: Nature medicine [Nat Med] 2024 Aug; Vol. 30 (8), pp. 2377.

Interruptions in bladder cancer care during the COVID-19 public health emergency.

Autor: Gore JL; Department of Urology, University of Washington, Seattle, WA. Electronic address: jlgore@uw.edu., Follmer K; Department of Urology, University of Washington, Seattle, WA., Reynolds J; Department of Urology, University of Washington, Seattle, WA., Nash M; Department of Biostatistics, University of Washington, Seattle, WA., Anderson CB; Department of Urology, Columbia University Medical Center, New York, NY., Catto JWF; Department of Urology, Sheffield Teaching Hospitals NHS (National Health Service) Foundation Trust, Sheffield, United Kingdom., Chamie K; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA., Daneshmand S; Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA., Dickstein R; University of Maryland Medical Center, Baltimore Washington Medical Center, Glen Burnie, MD; Chesapeake Urology, Baltimore, MD., Garg T; Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA., Gilbert SM; Division of Genitourinary Oncology, H.Lee Moffitt Cancer Center and Research Institute, Tampa FL., Guzzo TJ; Division of Urology, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA., Kamat AM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX., Kates MR; Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD., Lane BR; Division of Urology, Spectrum Health, Grand Rapids, MI., Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX., Mansour AM; Department of Urology, University of Texas Health, San Antonio, TX., Master VA; Department of Urology and Winship Cancer Institute, Emory University, Atlanta, GA., Montgomery JS; Department of Urology, Michigan Medicine, Ann Arbor, MI., Morris DS; Urology Associates, PC, Nashville, TN., Nepple KG; Department of Urology, University of Iowa, Iowa City, IA., O'Neil BB; Division of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Patel S; Department of Urology, University of Oklahoma, Oklahoma City, OK., Pohar K; Department of Urology, The Ohio State University, Columbus, OH., Porten SP; Department of Urology, UCSF School of Medicine, San Francisco, CA., Riggs SB; Department of Urology, Levine Cancer Institute, Atrium Health, Charlotte, NC., Sankin A; Department of Urology, Montefiore Medical Center, Bronx, NY., Scarpato KR; Department of Urology, Vanderbilt University Medical Center, Nashville, TN., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC., Steinberg GD; Department of Urology, Rush University Medical Center, Chicago, IL., Strope SA; Urology of St. Louis, St. Louis, MO., Taylor JM; Michael E. DeBakey VAMC, Scott Department of Urology, Baylor College of Medicine, Houston, TX., Comstock BA; Department of Biostatistics, University of Washington, Seattle, WA., Kessler LG; Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle, WA., Wolff EM; Department of Urology, University of Washington, Seattle, WA., Smith AB; Department of Urology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Publikováno v: Urologic oncology [Urol Oncol] 2024 Apr; Vol. 42 (4), pp. 116.e17-116.e21. Date of Electronic Publication: 2023 Dec 11.

Expression and mutagenesis studies in the Medicago truncatula iron transporter MtVTL8 confirm its role in symbiotic nitrogen fixation and reveal amino acids essential for transport.

Autor: Cai J; Department of Biological Sciences and BioDiscovery Institute, University of North Texas, Denton, TX, United States., Longo A; Department of Biological Sciences and BioDiscovery Institute, University of North Texas, Denton, TX, United States., Dickstein R; Department of Biological Sciences and BioDiscovery Institute, University of North Texas, Denton, TX, United States.

Publikováno v: Frontiers in plant science [Front Plant Sci] 2024 Jan 04; Vol. 14, pp. 1306491. Date of Electronic Publication: 2024 Jan 04 (Print Publication: 2023).

Corrigendum to "Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes" [Eur. Urol. Focus (2023)].

Autor: Linehan J; Providence Specialty Medical Group, Santa Monica, CA, USA., Gottlieb J; Providence Specialty Medical Group, Santa Monica, CA, USA. Electronic address: jgottlie55@gmail.com., Woldu SL; University of Texas Southwestern Medical Center, Dallas, TX, USA., Labbate C; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rose K; Moffitt Cancer Center, Tampa, FL, USA., Sexton W; Moffitt Cancer Center, Tampa, FL, USA., Kaimakliotis H; Indiana University Medical Center, Indianapolis, IN, USA., Jacob J; State University of New York Upstate Medical Center, Syracuse, NY, USA., Dickstein R; University of Maryland Medical Center, Baltimore Washington Medical Center, Glen Burnie, MD, USA; Chesapeake Urology, Baltimore, MD, USA., Nieder A; Mount Sinai Medical Center, Miami Beach, FL, USA., Bjurlin M; University of North Carolina Medical Center, Chapel Hill, NC, USA., Humphreys M; Mayo Clinic Cancer Center, Phoenix, AZ, USA., Ghodoussipour S; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Quek M; Loyola University Medical Center, Maywood, IL, USA., O'Donnell M; University of Iowa Health Care, Iowa City, IA, USA., Eisner BH; Massachusetts General Hospital, Boston, MA, USA., Feldman AS; Massachusetts General Hospital, Boston, MA, USA., Matin SF; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lotan Y; University of Texas Southwestern Medical Center, Dallas, TX, USA., Murray KS; NYU Langone Health, New York, NY, USA.

Publikováno v: European urology focus [Eur Urol Focus] 2024 Jan; Vol. 10 (1), pp. 211. Date of Electronic Publication: 2023 Aug 26.